Immunovant (IMVT) PT Raised to $57 at Stifel
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/27/2026
- Wall St rises as AI momentum holds heading into key earnings, Fed decision
- Meta's $97.5B AI money grab: why Zuckerberg is racing to raise cash before rivals
- Deutsche Bank’s Reid sees potential final dip this year before Santa rally
- UPS tops estimates as efficiency drive gains momentum
- GM to move stock listing to Nasdaq in November, shares gain
Tweet
Share
E-mailGet Alerts IMVT Hot Sheet
Price: $28.60 +1.53%
Rating Summary:
16 Buy, 6 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 8 | Down: 17 | New: 17
Rating Summary:
16 Buy, 6 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 8 | Down: 17 | New: 17
Join SI Premium – FREE
Stifel analyst Alex Thompson raised the price target on Immunovant (NASDAQ: IMVT) to $57.00 (from $49.00) while maintaining a Buy rating.
You May Also Be Interested In
- Canaccord Downgrades Botanix Pharmaceuticals Ltd (BOT:AU) to Hold
- Innio NV (INIO) PT Lowered to $35 at BNP Paribas Exane
- PrairieSky Royalty Ltd (PSK:CN) (PREKF) PT Raised to Cdn$38.75 at CIBC
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
